A Study to Evaluate the Safety of DAYVIGO (Lemborexant) Tablets in Participants With Insomnia.

CompletedOBSERVATIONAL

Enrollment

550

Participants

Timeline

Start Date

October 17, 2020

Primary Completion Date

March 17, 2022

Study Completion Date

March 17, 2022

Conditions

Sleep Initiation and Maintenance Disorders

Interventions

DRUG

Lemborexant

Lemborexant oral tablets.

Trial Locations (3)

Eisai trial site 1, Nagoya

Eisai trial site 2, Osaka

Eisai trial site 3, Tokyo

All Listed Sponsors

lead

Eisai Co., Ltd.

INDUSTRY

NCT04573556 - A Study to Evaluate the Safety of DAYVIGO (Lemborexant) Tablets in Participants With Insomnia. | Biotech Hunter | Biotech Hunter